Luca Licata, MD

Medical Oncologist, Breast Cancer Group - San Raffaele Scientific Institute

[Luca Licata, MD @LLicata88]

📢1/8 A subset of ER+/HER2- #breastcancer may benefit from #immunotherapy, but which tumors are these?🤔

Our latest study just out on @BrJCancer @SpringerNature sheds light on this highly relevant topic

Read more:📌https://t.co/dYiTmDEsJ5

@BianchiniGP @mauricallari

[Giulia Notini @NotiniGiulia]

🧵 1/10

Do you know everything about Trop2? 🤔

In this pan-cancer multi-omic analysis, we explored TACSTD2 expression, regulation, and biological associations across normal tissues and tumor types.

🔗https://t.co/WhTZRfT62R

[Giampaolo Bianchini @BianchiniGP]

🔥 Who truly benefits from immune checkpoint inhibitors in early triple-negative breast cancer (#TNBC)?
Precision immunology is a major unmet need
✅Key finding: on-treatment complement baseline biopsies
Immunity is dynamic, not a snapshot
Link and more 👇👇👇
@Annals_Oncology

[Over @OverEventi]

Highlights del corso FAD
Triple-Negative Breast Cancer (R)evolution: not so negative anymore – focus sugli ADCs
📅 Dall’1 marzo al 31 dicembre 2026

Un aggiornamento FAD sui nuovi approcci di trattamento, con particolare focus sugli antibody–drug conjugates (ADCs) e sul loro impatto nella pratica clinica.
Attraverso tre lezioni complementari verranno approfonditi:
- i principali studi clinici sugli ADCs
- il loro ruolo nelle diverse linee terapeutiche
- la gestione pratica delle pazienti

Responsabile scientifico: Giampaolo Bianchini @BianchiniGP
Relatori: G. Bianchini, Luca Licata @LLicata88 .

➡️ Iscrizioni aperte sul sito Over:
https://t.co/lYgYn80GQN

#BreastCancer #TNBC #ADCs #Oncologia #FormazioneMedica #FAD #Healthcare

[Giampaolo Bianchini @BianchiniGP]

🔥(1/7) Finally out after a very long journey, the main results from the BioItaLEE trial: a prospective study primarily aimed to evaluate ctDNA dynamics during 1st line ribo/let. A huge team effort with many Italian colleagues and friends 🇮🇹
👇👇 thread🧵
https://t.co/n2fQ42crFv

[Mirrors of Medicine @mirrorsmed]

De-escalation strategies for axillary management at primary surgery in early breast cancer: insights and implications for medical oncology practice

https://t.co/lZqpBoCsEl

Axillary surgery in early #BreastCancer has progressively shifted toward de-escalation to reduce morbidity while maintaining oncologic safety. Evidence supports omission of ALND in patients with limited sentinel node involvement and even omission of SLNB in selected low-risk groups. However, reduced axillary staging may affect eligibility for modern adjuvant therapies, including CDK4/6 and PARP inhibitors, underscoring the need for individualized, multidisciplinary decision-making to balance de-escalation with accurate treatment guidance.

@IPersano_
@LLicata88
@CarloBoMD
@AlessiaRognone
@BianchiniGP
Giulia Viale

[Yakup Ergün @dr_yakupergun]

De-escalation strategies for axillary management at primary surgery in early breast cancer: insights and implications for medical oncology practice
https://t.co/ttQDsor8JF

[Paolo Tarantino @PTarantinoMD]

How to treat HR+/HER2- with metastatic recurrence after adjuvant CDK4/6 inhibitors? Well… nobody knows. If you wanna help figure this out, join this survey! ➡️ https://t.co/RCsEoThJy6

[Luca Licata, MD @LLicata88]

@oncodaily @OncoAlert

[Luca Licata, MD @LLicata88]

📣Another step forward for #precision_immunotherapy in breast cancer!

🚀Just out in @Nature_NPJ Breast Cancer our exploratory analysis of the NeoTRIP trial showing the role of tumor-specific MHC-II as a predictor of immunotherapy benefit in #TNBC.

📌https://t.co/UVIAAifv8t

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

Don't miss this research brief on the timing of recurrence after neoadjuvant chemo-immunotherapy in early-stage #TripleNegativeBreastCancer.
🔓https://t.co/moUmVd9rbp
@LLicata88 @mariani_m97 @RebeccaDSing @stolaney1 @ErikaHamilton9 @YaleBreast @BianchiniGP #BreastCancer #bcsm #TNBC

[Mirrors of Medicine @mirrorsmed]

Timing of Recurrence After Neoadjuvant Chemo-Immunotherapy in Early-Stage Triple-Negative Breast Cancer

https://t.co/jgT4oJZJpj

This analysis of five clinical trials evaluating neoadjuvant chemo-immunotherapy in early-stage triple-negative #BreastCancer (TNBC) highlights that the majority of recurrences—ranging from 64.6% to 82.9%—occur within the first 24 months after treatment. The risk of early relapse was particularly high among patients with residual disease following therapy, while those who achieved a pathological complete response experienced a more balanced distribution of early and late events.

These findings underscore an urgent need for targeted clinical trials focused on high-risk TNBC patients who recur early, to develop more effective post-neoadjuvant treatment strategies and improve long-term outcomes.

@LLicata88
@mariani_m97
@giu_viale
@RebeccaDSing
@stolaney1
@ErikaHamilton9
@c_sotiriou
@BianchiniGP

[Elia Seguí, MD @elia_segui]

New in @CCR_AACR: Neoadj. CT+IO improves pCR, EFS & OS in TNBC, but among those who relapse, most do so early (<24m)—especially in pts with residual disease (see below). Urgent need for trials in this high-risk group: ICI+ADC? ICI+VEGF? Bispecifics?
🔗 https://t.co/moYi9DtZmv

[Luca Licata, MD @LLicata88]

@benjiwal @mariani_m97 @giu_viale @ErikaHamilton9 @stolaney1 @RebeccaDSing @BianchiniGP @SanRaffaeleMI @OncoAlert @oncodaily @AACR @VJOncology Great point! Indeed, we analyzed the recurrence patterns in pts with RD treated with chemo alone, and there didn’t appear to be any significant differences compared to those treated with chemo/immuno (see Suppl. Fig. 1). Thank you so much! 😃

[Luca Licata, MD @LLicata88]

🚨Just out in @CCR_AACR our analysis on the recurrence timing after neoadjuvant chemo-immunotherapy in early-stage TNBC

We analyzed 5 major trials
👉 Early relapse: up to 83% of all recurrences🤯

1/ 🧵 Why this matters 👇

🔗 Full article: https://t.co/kih7813mKs

[Luca Licata, MD @LLicata88]

4/🧵
🙏 Grateful to work with an amazing team: @mariani_m97 @giu_viale @ErikaHamilton9 @stolaney1 @RebeccaDSing Peter Schmid, Christos Sotiriou, Lajos Pusztai and, of course...
@BianchiniGP

@SanRaffaeleMI @OncoAlert @oncodaily @AACR @VJOncology

[Luca Licata, MD @LLicata88]

3/🧵
⚠️ Most relapses happen fast: within 18m from randomization (DFI < 6m)

🚫 These patients are routinely excluded from trials

🧪 Urgent need to design studies targeting this high-risk group — industry & academia, take note!

[Giampaolo Bianchini @BianchiniGP]

🔥 Camizestrant in SERENA-6 study demonstrated highly statistically significant and clinical meaningful ⬆️ PFS

A landmark trial in oncology history: shifting treatment based on molecular (not clinical) progression by targeting its biological driver

https://t.co/MCXYbR3VUT!

[Luca Licata, MD @LLicata88]

Just out on @JAMANetworkOpen our study on the fate of immunotherapy trials in breast cancer, led by @mariani_m97

Take a look at the terrific job and excellent tweetorial he did 👏

@BianchiniGP @SanRaffaeleMI @OncoAlert

[Marco Mariani @mariani_m97]

Excited to share our latest publication on @JAMANetworkOpen : "Completion rate and positive results reporting among immunotherapy trials in breast cancer, 2004-2023.”
#BreastCancerResearch @OncoAlert @SanRaffaeleMI

👇Check out some key insights below

[Carmen Criscitiello @CarmenCriscit]

Fantastic talk by @BianchiniGP at #ASCO2024 : "Does the Target Matter?" re ADCs. Must say, the insights were top-notch! But full disclosure: I might be a bit biased! 😅 #CancerResearch #ADCs